Advertisement
Screener

Verastem, Inc. (VSTM) Payments to Acquire Investments

2.2 / 5 stars · 29/66 Roast Me

Verastem, Inc. Payments to Acquire Investments

Verastem, Inc. (VSTM) reported Payments to Acquire Investments of $60.22 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-07.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireInvestments · last filed 2016-11-07

  • Verastem, Inc. payments to acquire investments for the quarter ending 2016-09-30 was $19.82M, a 64.71% decline year-over-year.
  • Verastem, Inc. payments to acquire investments for the quarter ending 2016-06-30 was $4.05M, a 76.17% decline year-over-year.
  • Verastem, Inc. payments to acquire investments for the quarter ending 2016-03-31 was $36.35M, a 53.60% decline year-over-year.
  • Verastem, Inc. payments to acquire investments for the quarter ending 2015-12-31 was $48.35M, a 611.97% increase year-over-year.
  • Verastem, Inc. payments to acquire investments for fiscal 2015 was $199.85M, a 407.74% increase from fiscal 2014.
  • Verastem, Inc. payments to acquire investments for fiscal 2014 was $39.36M, a 66.70% decline from fiscal 2013.
  • Verastem, Inc. payments to acquire investments for fiscal 2013 was $118.19M, a 23.27% decline from fiscal 2012.
  • Verastem, Inc. payments to acquire investments for fiscal 2012 was $154.03M, a 329.63% increase from fiscal 2011.
Period endPayments to Acquire Investments 3 monthPayments to Acquire Investments 6 monthPayments to Acquire Investments 9 monthPayments to Acquire Investments 12 monthPayments to Acquire Investments 20 monthPayments to Acquire Investments 23 monthPayments to Acquire Investments 26 monthPayments to Acquire Investments 29 monthPayments to Acquire Investments 32 monthPayments to Acquire Investments 35 monthPayments to Acquire Investments 38 monthPayments to Acquire Investments 41 monthPayments to Acquire Investments 44 month
2016-09-30$19.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$23.88M
derived: sum of 2 quarters · filed 2016-11-07
$60.22M
10-Q · filed 2016-11-07
$108.57M
derived: sum of 4 quarters · filed 2016-11-07
2016-06-30$4.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$40.40M
10-Q · filed 2016-08-08
$88.75M
derived: sum of 3 quarters · filed 2016-08-08
$144.92M
derived: sum of 4 quarters · filed 2016-11-07
2016-03-31$36.35M
10-Q · filed 2016-05-09
$84.70M
derived: sum of 2 quarters · filed 2016-05-09
$140.86M
derived: sum of 3 quarters · filed 2016-11-07
$157.87M
derived: sum of 4 quarters · filed 2016-11-07
2015-12-31$48.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
$104.52M
derived: sum of 2 quarters · filed 2016-11-07
$121.53M
derived: sum of 3 quarters · filed 2016-11-07
$199.85M
10-K · filed 2016-03-03
2015-09-30$56.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$73.17M
derived: sum of 2 quarters · filed 2016-11-07
$151.50M
10-Q · filed 2016-11-07
$158.29M
derived: sum of 4 quarters · filed 2016-11-07
2015-06-30$17.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$95.33M
10-Q · filed 2016-08-08
$102.12M
derived: sum of 3 quarters · filed 2016-08-08
$108.05M
derived: sum of 4 quarters · filed 2016-08-08
2015-03-31$78.33M
10-Q · filed 2016-05-09
$85.12M
derived: sum of 2 quarters · filed 2016-05-09
$91.05M
derived: sum of 3 quarters · filed 2016-05-09
$108.52M
derived: sum of 4 quarters · filed 2016-05-09
2014-12-31$6.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
$12.72M
derived: sum of 2 quarters · filed 2016-03-03
$30.19M
derived: sum of 3 quarters · filed 2016-03-03
$39.36M
10-K · filed 2016-03-03
2014-09-30$5.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$23.40M
derived: sum of 2 quarters · filed 2015-11-09
$32.57M
10-Q · filed 2015-11-09
$47.40M
derived: sum of 4 quarters · filed 2016-03-03
2014-06-30$17.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
$26.64M
10-Q · filed 2015-08-10
$41.47M
derived: sum of 3 quarters · filed 2016-03-03
$100.62M
derived: sum of 4 quarters · filed 2016-03-03
2014-03-31$9.17M
10-Q · filed 2015-05-11
$24.00M
derived: sum of 2 quarters · filed 2016-03-03
$83.15M
derived: sum of 3 quarters · filed 2016-03-03
$100.14M
derived: sum of 4 quarters · filed 2016-03-03
$317.24M
10-Q · filed 2014-05-08
2013-12-31$14.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
$73.98M
derived: sum of 2 quarters · filed 2016-03-03
$90.97M
derived: sum of 3 quarters · filed 2016-03-03
$118.19M
10-K · filed 2016-03-03
$308.07M
10-K · filed 2014-03-06
2013-09-30$59.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30
$76.14M
derived: sum of 2 quarters · filed 2014-10-30
$103.36M
10-Q · filed 2014-10-30
$111.48M
derived: sum of 4 quarters · filed 2015-03-10
$293.24M
10-Q · filed 2013-11-12
2013-06-30$16.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$44.21M
10-Q · filed 2014-08-07
$52.33M
derived: sum of 3 quarters · filed 2015-03-10
$81.31M
derived: sum of 4 quarters · filed 2015-03-10
$234.09M
10-Q · filed 2013-08-13
2013-03-31$27.22M
10-Q · filed 2014-05-08
$35.34M
derived: sum of 2 quarters · filed 2015-03-10
$64.32M
derived: sum of 3 quarters · filed 2015-03-10
$108.49M
derived: sum of 4 quarters · filed 2015-03-10
$217.10M
10-Q · filed 2013-05-09
2012-12-31$8.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-10
$37.10M
derived: sum of 2 quarters · filed 2015-03-10
$81.27M
derived: sum of 3 quarters · filed 2015-03-10
$154.03M
10-K · filed 2015-03-10
$189.88M
10-K · filed 2013-03-26
2012-09-30$28.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$73.15M
derived: sum of 2 quarters · filed 2013-11-12
$145.91M
10-Q · filed 2013-11-12
$181.76M
10-Q · filed 2012-11-13
2012-06-30$44.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13
$116.92M
10-Q · filed 2013-08-13
$152.77M
10-Q · filed 2012-08-13
2012-03-31$72.76M
10-Q · filed 2013-05-09
$108.61M
10-Q · filed 2012-05-14
2011-12-31$35.85M
10-K · filed 2014-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Faeth Therapeutics, Inc. (FTH)United States$0.750B
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Wave Life Sciences, Inc. (WVE)$0.780B-5.56